These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36192390)

  • 1. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.
    Conroy F; Miller R; Alterman JF; Hassler MR; Echeverria D; Godinho BMDC; Knox EG; Sapp E; Sousa J; Yamada K; Mahmood F; Boudi A; Kegel-Gleason K; DiFiglia M; Aronin N; Khvorova A; Pfister EL
    Nat Commun; 2022 Oct; 13(1):5802. PubMed ID: 36192390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
    Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
    Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs.
    Hu J; Liu J; Yu D; Aiba Y; Lee S; Pendergraff H; Boubaker J; Artates JW; Lagier-Tourenne C; Lima WF; Swayze EE; Prakash TP; Corey DR
    Nucleic Acid Ther; 2014 Jun; 24(3):199-209. PubMed ID: 24694346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
    van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
    Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.
    Yu D; Pendergraff H; Liu J; Kordasiewicz HB; Cleveland DW; Swayze EE; Lima WF; Crooke ST; Prakash TP; Corey DR
    Cell; 2012 Aug; 150(5):895-908. PubMed ID: 22939619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.
    Fiszer A; Olejniczak M; Switonski PM; Wroblewska JP; Wisniewska-Kruk J; Mykowska A; Krzyzosiak WJ
    BMC Mol Biol; 2012 Mar; 13():6. PubMed ID: 22397573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
    Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
    Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.
    Østergaard ME; Southwell AL; Kordasiewicz H; Watt AT; Skotte NH; Doty CN; Vaid K; Villanueva EB; Swayze EE; Bennett CF; Hayden MR; Seth PP
    Nucleic Acids Res; 2013 Nov; 41(21):9634-50. PubMed ID: 23963702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells.
    Drouet V; Ruiz M; Zala D; Feyeux M; Auregan G; Cambon K; Troquier L; Carpentier J; Aubert S; Merienne N; Bourgois-Rocha F; Hassig R; Rey M; Dufour N; Saudou F; Perrier AL; Hantraye P; Déglon N
    PLoS One; 2014; 9(6):e99341. PubMed ID: 24926995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
    Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
    Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.
    Hu J; Liu J; Corey DR
    Chem Biol; 2010 Nov; 17(11):1183-8. PubMed ID: 21095568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene targeting techniques for Huntington's disease.
    Fields E; Vaughan E; Tripu D; Lim I; Shrout K; Conway J; Salib N; Lee Y; Dhamsania A; Jacobsen M; Woo A; Xue H; Cao K
    Ageing Res Rev; 2021 Sep; 70():101385. PubMed ID: 34098113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities.
    Oikemus SR; Pfister EL; Sapp E; Chase KO; Kennington LA; Hudgens E; Miller R; Zhu LJ; Chaudhary A; Mick EO; Sena-Esteves M; Wolfe SA; DiFiglia M; Aronin N; Brodsky MH
    Hum Gene Ther; 2022 Jan; 33(1-2):25-36. PubMed ID: 34376056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivering a disease-modifying treatment for Huntington's disease.
    Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF
    Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.
    Boudreau RL; Spengler RM; Davidson BL
    Mol Ther; 2011 Dec; 19(12):2169-77. PubMed ID: 21952166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.